Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement

Virology

Volumn 245, Issue 1, 1998, Pages 151-162

  Raabe, Michelle L ^a   Issel, Charles J ^b   Cook, Sheila J ^b   Cook, R Frank ^b   Woodson, Bruce ^a   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EQUINE INFECTIOUS ANEMIA VIRUS; FEVER; HORSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTOPENIA; VACCINE PRODUCTION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; EQUUS CABALLUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES; UNIDENTIFIED BACULOVIRUS;

EID: 0032565690     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9142     Document Type: Article

References (37)

1. Ahmad S., Lohman B., Marthas M., Giavedoni L., El-Amad Z., Haigwood N., Scandella C., Gardner M., Luciw P., Yilma T. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res. Hum. Retroviruses. 10:1994;195-204.
2. Baldinotti F., Matteucci D., Mazzetti P., Giannelli C., Bandecchi P., Tozzini F., Bendinelli M. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J. Virol. 68:1994;4572-4579.
3. Bolognesi D. Do antibodies enhance infection of cells by HIV. Nature. 340:1989;431-432.
4. Burke D. Human HIV vaccine trials: Does antibody-dependent enhancement pose a genuine risk. Perspect. Biol. Med. 35:1992;511-530.
5. Costa L. R., Issel C. J., Montelaro R. C., Cook S. J., Cook R. F., Rushlow K. E., Grund C., Wang S. Responses to ponies to challenge with equine infectious anemia virus following exposure to recombinant gp90 or viral p26 immunogens. Equine Infectious Diseases. 7:1994;85-94.
6. Dolin R., Graham B. S., Greenberg S. B., Tacket C. O., Belshe R. B., Midthun K., Clements M. L., Gorse G. J., Horgan B. W., Atmar R. L., Karzon D. T., Bonnez W., Fernie B. F., Montefiori D. C., Stablen D. M., Smith G. E., Koff W. C. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann. Intern. Med. 114:1991;119-127.
7. Halsted S. Immune enhancement of viral infection. Prog. Allergy. 31:1982;301-364.
8. Hammond S. A., Cook S. J., Lichtenstein D. L., Issel C. J., Montelaro R. C. Maturation of the cellular and humoral immune response to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:1997;3840-3852.
9. Homsy J., Meyer M., Levy J. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol. 64:1990;1437-1440.
10. Homsy J., Tateno M., Levy J. Antibody-dependent enhancement of HIV infection. Lancet. i:1988;1285-1286.
11. Hosie M., Osborne R., Reid G., Neil J., Oswald J. Enhancement after feline immunodeficiency virus vaccination. Vet. Immunol. Immunopathol. 35:1992;191-197.
12. Issel C. J., Horohov D. W., Lea D. F., Adams W. V. Jr., Hagius S. D., McManus J. M., Allison A. C., Montelaro R. C. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J. Virol. 66:1992;3398-3408.
13. Jolly P. E., Huso D. L., Sheffer D., Narayan O. Modulation of lentivirus replication by antibodies: Fc portion of immunoglobulin molecule is essential for enhancement of binding, internalization, and neutralization of visna virus in macrophages. J. Virol. 63:1989;1811-1813.
14. Keefer M. C., Graham B. S., Belshe R. B., Schwartz D., Corey L., Bolognesi D. P., Stablein D. M., Montefiori D. C., McElrath M. J., Clements M. L., Gorse G. J., Wright P. F., Matthews T. J., Smith G. E., Lawrence D., Dolin R. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res. Hum. Retroviruses. 10:1994;1713-1723.
15. Kliks S., Nisalak A., Brandt W., Wahl L., Burde D. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:1989;444-451.
16. Lichtenstein D. L., Rushlow K. E., Cook R. F., Raabe M. L., Swardson C. J., Kociba G. J., Issel C. J., Montelaro R. C. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity. J. Virol. 69:1995;2881-2888.
17. Lombardi S., Garzelli C., Pistello M., Massi C., Matteucci D., Baldinotti F., Cammarota G., Prato L., Bandecchi P., Tozzini F., Bendinelli M. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J. Virol. 68:1994;8374-8379.
18. Malmquist W. A., Barnett D., Becvar C. S. Production of equine infectious anemia antigen in a persistently infected cell line. Arch. Virol. 42:1973;361-370.
19. Mascola J. R., Mathieson B. J., Zack P. M., Walker M. C., Halstead S. B., Burke D. S. Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res. Hum. Retroviruses. 9:1992;1175-1184.
20. McCoy H. A Study of Recombinant Major Core Proteins (rp26) and Transmembrane Proteins (rgp45) as Immunogens for Equine Infectious Anemia Virus. 1995;University of Kentucky.
21. McElrath M. J., Corey L., Greensberg P. D., Matthews T. J., Montefiori D. C., Rowen L., Hood L., Mullins J. I. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA. 93:1996;3972-3977.
22. Montefiori D., Murphey-Corb M., Desrosiers R., Daniel M. Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J. Virol. 64:1990a;5223-5225.
23. Montefiori D., Robinson W., Hirsch V., Modliszewski A., Mitchell W., Johnson P. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J. Virol. 64:1990b;113-119.
24. Montelaro R. C., Ball J. M., Rushlow K. E. Equine retroviruses. The Retroviridae. 1993;Plenum, New York. p. 257-360.
25. Montelaro R. C., Bolognesi D. P. Vaccines Against Retroviruses. Levy J. A. The Retrovirdae. 1995;605-645 Plenum, New York.
26. Olsen C., Corapi W., Ngichabe C., Baines J., Scott F. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J. Virol. 66:1992;956-965.
27. Pearson J. I., Coggins L. Protocol for the immunodiffusion (Coggins) test for equine infectious anemia. Proc. Am. Assoc. Vet. Lab. Diag. 22:1979;449-462.
28. Porterfield J. S. Antibody-dependent enhancement of viral infectivity. J. Adv. Virus Res. 31:1986;335-353.
29. Richardson J., Moraillon A., Baud S., Cuisinier A.-M., Sonigo P., Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J. Virol. 71:1997;9640-9649.
30. Robinson W., Montefiori D., Mitchell W. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet. 1:1988a;790-794.
31. Robinson W. E., Montefiori D. C., Mitchell W. M. Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines. Lancet. 1:1988b;830-831.
32. Rwambo P. M., Issel C. J., Adams W. Jr., Hussain K. A., Miller M., Montelaro R. C. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistant infection. Arch. Virol. 111:1990;199-212.
33. Siebelink K., Tijhaar E., Huisman R., Huisman W., DE Ronde A., Darby I., Francis M., Rimmelzwaan G., Osterhaus A. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J. Virol. 69:1995;3704-3711.
34. Tamura, M. Webster, R. G. Ennis, F. A. 1994, Subtype cross-reactive, infection-enhancing antibody responses to Influenza A viruses.
35. Vennema H., DE Groot R., Harbour D., Dalderup M., Gruffydd-Jones T., Horzinek M., Spaan W. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 64:1990;1407-1409.
36. Wang S., Rushlow K., Issel C., Cook R., Cook S., Raabe M., Chong Y.-H., Costa L., Montelaro R. C. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology. 199:1994;247-251.
37. Weiss R., Scott F. Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever. Comp. Immun. Microbiol. Infect. Dis. 4:1981;175-189.